- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | Cereno Scientific - CS014 (thrombosis) progresses towards the clinic | 159 | Edison Investment Research | Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA)... ► Artikel lesen | |
| 16.04. | Report from Annual General Meeting 2024 of Cereno Scientific AB | 2 | Cision News | ||
| 11.04. | Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family | 1 | Cision News | ||
| 10.04. | Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014 | 1 | Cision News | ||
| 09.04. | Cereno Scientific announces extended patent protection in Europe for CS585 program | 1 | Cision News | ||
| 03.04. | Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific | 1 | Cision News | ||
| 28.03. | Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH | 3 | Cision News | ||
| 27.03. | Cereno Scientific releases Insights Video Season 3 Episode 8 with Björn Dahlöf, CSO, Cereno Scientific | 1 | Cision News | ||
| 26.03. | Cereno Scientific publishes Annual Report for 2023 | 3 | Cision News | ||
| 25.03. | Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community | 3 | Cision News | ||
| 22.03. | Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1 | 1 | Cision News | ||
| 21.03. | Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov | 1 | Cision News | ||
| 21.03. | Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million | 1 | Cision News | ||
| 19.03. | Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1 | 1 | Cision News | ||
| 14.03. | Don de Bethizy has been engaged as Senior Advisor to the Executive Management and Board of Directors of Cereno Scientific | 1 | Cision News | ||
| 14.03. | Cereno Scientific brings forward the publication of the Annual Report | 2 | Cision News | ||
| 14.03. | Last day of trading with warrants of series TO3 in Cereno Scientific is today, March 14, 2024 | 1 | Cision News | ||
| 13.03. | Cereno Scientific to attend BIO-Europe Spring in Barcelona, March 18-20, 2024 | 1 | Cision News | ||
| 12.03. | BioStock has published an interview with Cereno Scientific's CMO and Head of R&D, Dr. Rahul Agrawal | 1 | Cision News | ||
| 12.03. | CERENO SCIENTIFIC: Cereno's new CMO and Head of R&D comments on progress with CS1 | 1 | Cision News |
Seite:
1 2 3 4 Weiter >>
74 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,605 | -1,59 % | Große Unruhe im BioTech-Sektor! Evotec und Medigene vor Ausbruch, Bayer und BioNTech stottern! | Der DAX 40-Index hat in 2024 bereits einen großen Lauf hinter sich gebracht. Getrieben von den Hightech-Werten der NASDAQ konnte Anfang April ein Hoch von 18.567 Punkten erreicht werden. Die ehemaligen... ► Artikel lesen | |
| QIAGEN | 39,625 | -0,79 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| BIONTECH | 85,40 | -0,81 % | Earnings call: BioNTech targets oncology growth, plans new COVID vaccine | ||
| DAY ONE BIOPHARMACEUTICALS | 16,600 | -3,32 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| CG ONCOLOGY | 35,100 | -3,23 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,940 | +1,13 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
| JANUX THERAPEUTICS | 62,19 | -4,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| IMMUNOVANT | 29,670 | +2,88 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
| KEROS THERAPEUTICS | 60,26 | -0,41 % | Keros Therapeutics files automatic mixed shelf | ||
| STRUCTURE THERAPEUTICS | 39,740 | +1,15 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights | Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 10,390 | +2,36 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MORPHOSYS | 66,90 | +0,38 % | ROUNDUP/Aktien Frankfurt Eröffnung: Dax legt weiter zu - Rekord rückt näher | FRANKFURT (dpa-AFX) - Der Dax hat am Montag weiter zugelegt. Nach dem starken Ausklang der vergangenen Woche reichte es in der ersten Handelsstunde für ein Plus von 0,28 Prozent auf 18 211,64 Punkte.... ► Artikel lesen | |
| ARVINAS | 32,260 | -1,77 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| ARCELLX | 52,67 | -0,04 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 20,600 | -3,69 % | Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,57 % bei einem Aktienkurs von 0,318 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
